At a glance
ClinicalIndex Comparison RecordN/ACompleted· 441 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-term Results of Plasma Epstein-Barr Virus DNA Monitoring In Nasopharyngeal Carcinoma After Curative Treatment
In Brief
An observational study for Nasopharyngeal Carcinoma and 3 related conditions. Completed, enrolled 441 participants across 1 site.
Detailed Summary
Continuous regular monitoring of plasma EBV DNA in nasopharyngeal carcinoma (NPC) after treatment have rarely been investigated. The investigators try to analyze the long-term observational results (role in early relapse detection and impact on survival) in NPC patients after curative treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma, NPC, EBV, Radiotherapy
CountriesTaiwan
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
Primary CompletionDec 2013
Study CompletionApr 2019
First PostedJun 2019
TodayJul 2026
First PostedJun 4, 2019
Enrollment StartAug 1, 2011
Primary CompletionDec 31, 2013
Study CompletionApr 30, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 7.1 years ago